Tohru Kino's team

KinoPharma is a Japanese clinical-stage biotechnology company founded by Dr. Tohru Kino, the renowned scientist who discovered tacrolimus (FK506). The company specializes in the development of small molecule inhibitors targeting specific kinases, such as CDK9 and DYRK, to address viral infections and other high-unmet-need diseases. Its lead candidate, FIT039, is a CDK9 inhibitor currently in Phase 2 clinical trials for the treatment of Human Papillomavirus (HPV) related conditions, including cervical dysplasia and skin warts. KinoPharma's strategy focuses on modulating host cell factors to inhibit viral replication, providing a novel therapeutic approach compared to traditional direct-acting antivirals. The firm leverages deep expertise in natural product chemistry and kinase biology to drive its drug discovery engine.